Natco Pharma [NATCOPHARM] vs Laurus Labs [LAURUSLABS] Detailed Stock Comparison
Natco Pharma
NSE
Loading...
Laurus Labs
NSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Natco Pharma wins in 18 metrics, Laurus Labs wins in 2 metrics, with 0 ties. Natco Pharma appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Natco Pharma | Laurus Labs | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 9.33 | 93.42 | Natco Pharma |
| Price-to-Book Ratio | 2.08 | 10.60 | Natco Pharma |
| Debt-to-Equity Ratio | 3.67 | 60.05 | Natco Pharma |
| PEG Ratio | -0.33 | 0.08 | Natco Pharma |
| EV/EBITDA | 6.93 | 40.30 | Natco Pharma |
| Profit Margin (TTM) | 38.62% | 8.58% | Natco Pharma |
| Operating Margin (TTM) | 38.63% | 16.90% | Natco Pharma |
| EBITDA Margin (TTM) | 38.63% | 16.90% | Natco Pharma |
| Return on Equity | 24.77% | 7.79% | Natco Pharma |
| Return on Assets (TTM) | 21.85% | 3.84% | Natco Pharma |
| Free Cash Flow (TTM) | $11.85B | $-393.50M | Natco Pharma |
| Dividend Yield | 0.92% | 0.18% | Natco Pharma |
| 1-Year Return | -43.37% | 97.02% | Laurus Labs |
| Price-to-Sales Ratio (TTM) | 3.60 | 8.00 | Natco Pharma |
| Enterprise Value | $135.92B | $501.55B | Laurus Labs |
| EV/Revenue Ratio | 3.09 | 8.46 | Natco Pharma |
| Gross Profit Margin (TTM) | 82.47% | 59.39% | Natco Pharma |
| Revenue per Share (TTM) | $245 | $110 | Natco Pharma |
| Earnings per Share (Diluted) | $94.78 | $9.41 | Natco Pharma |
| Beta (Stock Volatility) | 0.19 | 0.36 | Natco Pharma |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Natco Pharma vs Laurus Labs Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Natco Pharma | -0.86% | 0.91% | -13.03% | 0.59% | 7.21% | -36.85% |
| Laurus Labs | -0.67% | 1.55% | 6.77% | 48.84% | 63.78% | 42.79% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Natco Pharma | -43.37% | 41.34% | 10.28% | 94.06% | 1,592.79% | 3,459.70% |
| Laurus Labs | 97.02% | 54.98% | 277.77% | 824.10% | 824.10% | 824.10% |
Performance & Financial Health Analysis: Natco Pharma vs Laurus Labs
| Metric | NATCOPHARM | LAURUSLABS |
|---|---|---|
| Market Information | ||
| Market Cap | ₹158.37B | ₹474.56B |
| Market Cap Category | Mid cap | Large cap |
| 10 Day Avg. Volume | 532,696 | 1,826,092 |
| 90 Day Avg. Volume | 958,882 | 2,704,210 |
| Last Close | ₹874.85 | ₹873.20 |
| 52 Week Range | ₹726.80 - ₹1,639.00 | ₹427.05 - ₹922.50 |
| % from 52W High | -46.62% | -5.34% |
| All-Time High | ₹1,639.00 (Sep 09, 2024) | ₹922.50 (Jul 30, 2025) |
| % from All-Time High | -46.62% | -5.34% |
| Growth Metrics | ||
| Quarterly Revenue Growth | -0.03% | 0.31% |
| Quarterly Earnings Growth | -0.28% | 12.03% |
| Financial Health | ||
| Profit Margin (TTM) | 0.39% | 0.09% |
| Operating Margin (TTM) | 0.39% | 0.17% |
| Return on Equity (TTM) | 0.25% | 0.08% |
| Debt to Equity (MRQ) | 3.67 | 60.05 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | ₹424.69 | ₹82.94 |
| Cash per Share (MRQ) | ₹139.41 | ₹2.67 |
| Operating Cash Flow (TTM) | ₹19.26B | ₹4.13B |
| Levered Free Cash Flow (TTM) | ₹18.85B | ₹3.58B |
| Dividends | ||
| Last 12-Month Dividend Yield | 0.92% | 0.18% |
| Last 12-Month Dividend | ₹8.00 | ₹1.20 |
Valuation & Enterprise Metrics Analysis: Natco Pharma vs Laurus Labs
| Metric | NATCOPHARM | LAURUSLABS |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 9.33 | 93.42 |
| Forward P/E | 21.42 | 37.62 |
| PEG Ratio | -0.33 | 0.08 |
| Price to Sales (TTM) | 3.60 | 8.00 |
| Price to Book (MRQ) | 2.08 | 10.60 |
| Market Capitalization | ||
| Market Capitalization | ₹158.37B | ₹474.56B |
| Enterprise Value | ₹135.92B | ₹501.55B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 3.09 | 8.46 |
| Enterprise to EBITDA | 6.93 | 40.30 |
| Risk & Other Metrics | ||
| Beta | 0.19 | 0.36 |
| Book Value per Share (MRQ) | ₹424.69 | ₹82.94 |
Financial Statements Comparison: Natco Pharma vs Laurus Labs
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | NATCOPHARM | LAURUSLABS |
|---|---|---|
| Revenue/Sales | ₹13.29B | ₹15.70B |
| Cost of Goods Sold | ₹2.33B | ₹6.37B |
| Gross Profit | ₹10.96B | ₹9.32B |
| Research & Development | N/A | N/A |
| Operating Income (EBIT) | ₹5.13B | ₹2.65B |
| EBITDA | ₹6.33B | ₹3.93B |
| Pre-Tax Income | ₹5.72B | ₹2.24B |
| Income Tax | ₹916.00M | ₹631.40M |
| Net Income (Profit) | ₹4.80B | ₹1.62B |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | NATCOPHARM | LAURUSLABS |
|---|---|---|
| Cash & Equivalents | ₹1.20B | ₹995.40M |
| Total Current Assets | ₹52.70B | ₹43.32B |
| Total Current Liabilities | ₹9.44B | ₹35.40B |
| Long-Term Debt | ₹46.00M | ₹7.08B |
| Total Shareholders Equity | ₹76.12B | ₹46.03B |
| Retained Earnings | N/A | ₹36.26B |
| Property, Plant & Equipment | ₹24.32B | ₹1.89B |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | NATCOPHARM | LAURUSLABS |
|---|---|---|
| Operating Cash Flow | N/A | N/A |
| Capital Expenditures | N/A | N/A |
| Free Cash Flow | N/A | N/A |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | NATCOPHARM | LAURUSLABS |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Average Daily Volume (10 Day) | 532,696 | 1,826,092 |
| Average Daily Volume (90 Day) | 958,882 | 2,704,210 |
| Shares Outstanding | 179.11M | 539.25M |
| Float Shares | 83.13M | 362.33M |
| % Held by Insiders | 0.51% | 0.32% |
| % Held by Institutions | 0.13% | 0.33% |
Dividend Analysis & Yield Comparison: Natco Pharma vs Laurus Labs
| Metric | NATCOPHARM | LAURUSLABS |
|---|---|---|
| Last 12-Month Dividend | ₹8.00 | ₹1.20 |
| Last 12-Month Dividend Yield | 0.92% | 0.18% |
| 3-Year Avg Annual Dividend | ₹6.50 | ₹1.33 |
| 3-Year Avg Dividend Yield | 0.24% | 0.16% |
| 3-Year Total Dividends | ₹19.50 | ₹4.00 |
| Ex-Dividend Date | Aug 19, 2025 | May 09, 2025 |